Krystal Biotech financials
$335.06−0.60%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $389.1M | $290.5M | $50.7M | $0.00 | $0.00 | — | — | — | — |
| Gross profit | $366.1M | $270.5M | $47.6M | $0.00 | $0.00 | — | — | — | — |
| Gross margin | 94.1% | 93.1% | 93.9% | — | — | — | — | — | — |
| Operating income | $161.3M | $65.7M | -$109.6M | -$145.2M | -$68.3M | -$33.0M | -$22.1M | -$11.9M | -$4.8M |
| Net income | $204.8M | $89.2M | $10.9M | -$140.0M | -$69.6M | -$32.2M | -$19.1M | -$10.9M | -$7.9M |
| Net margin | 52.6% | 30.7% | 21.6% | — | — | — | — | — | — |
| Diluted EPS | $6.84 | $3.00 | $0.39 | $-5.49 | $-3.13 | $-1.71 | $-1.20 | $-0.97 | $-1.48 |
| EBITDA | $167.0M | $109.2M | -$92.1M | -$117.6M | -$65.5M | -$31.1M | -$21.0M | -$11.8M | -$4.7M |
| Operating cash flow | $200.9M | $123.4M | -$88.8M | -$100.6M | -$47.9M | -$26.1M | -$18.7M | -$9.4M | -$3.9M |
| Free cash flow | $188.9M | $119.2M | -$100.6M | -$153.5M | -$116.3M | -$40.9M | -$25.1M | -$11.7M | -$4.1M |
| Diluted shares | 30.0M | 29.7M | 27.8M | 25.5M | 22.2M | 18.8M | 15.9M | 11.2M | 5.4M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $496.3M | $344.9M | $358.3M | $161.9M | $341.2M | $268.3M |
| Short-term investments | $331.5M | $252.7M | $173.8M | $217.3M | $96.8M | $3.0M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $1.33B | $1.06B | $818.4M | $558.5M | $626.3M | $310.8M |
| Total liabilities | $114.2M | $109.5M | $39.7M | $36.2M | $32.7M | $18.8M |
| Shareholders' equity | $1.22B | $946.4M | $778.6M | $522.2M | $593.6M | $292.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology